Commenting on news reports today (10 January 2014) regarding NICE proposals to assess new medicines on their benefit to wider society, Paul Catchpole, Value and Access Director at the ABPI, said:


​"We welcome the concept of NICE using a broader definition of value in its assessment of medicines in order to reflect more fully the value they bring to patients and society.

"We need to ensure that the new system encourages and endorses the use of the innovative medicines that patients need. It is too early to understand the impact that the new proposals will have on future access to medicines until they are published and we are looking forward to reviewing the detail of the proposals, as part of the consultation NICE will be conducting, when they become available."


Media enquiries

ABPI Press Office

Tel: +44 (0) 20 7747 1441

Mobile: +44 (0) 7850 312064


Notes to editor

The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.



Print this page icon Print this page
Please choose the subject of your enquiry from the list below:
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.